Eli Lilly nears a deal to acquire psychedelic drugmaker Atai Beckley in a move that could expand its pipeline of mental health treatments and reshape industry competition

Eli Lilly is nearing a deal to acquire psychedelic drugmaker Atai Beckley, signaling deeper pharmaceutical interest in psychedelic-based mental health treatments. The potential acquisition points to growing competition around drug development for conditions such as depression and other psychiatric disorders. Atai Beckley appears positioned as a specialist in psychedelic therapeutics, making the deal notable for both biotech consolidation and the mainstreaming of this treatment area. Large drugmakers have increasingly looked to novel neuropsychiatric pipelines as traditional psychiatric innovation has lagged and investor attention has shifted toward faster-growing mental health markets. The move could strengthen Eli Lilly's presence in experimental psychiatric medicine while accelerating clinical development, partnerships, and regulatory positioning across the psychedelic sector. It also suggests that psychedelic drug companies are becoming credible acquisition targets for major pharmaceutical firms.